Personalized Med Dx Patent Reaffirmed By Machine-Or-Transformation Test
This article was originally published in The Gray Sheet
Executive Summary
A federal appeals court reaffirmed the patentability of certain personalized medicine diagnostic claims, but it relied on a legal test that diagnostic and biotech firms have complained is overly restrictive.
You may also be interested in...
Supreme Court Overturns Personalized Medicine Patents, Creating Confusion In Diagnostics Realm
High court rules the processes covered by two patents to determine proper drug dosages based on metabolite concentrations do not transform unpatentable natural laws into patent-eligible applications.
Is That A Diagnostic Method Patent Or A Law Of Nature? Supreme Court Hears Arguments
A case argued before the Supreme Court Dec. 7 offers the justices an opportunity to place stricter limits on the types of claims that diagnostic makers can latch onto for patent protection. But while the justices had many questions on appropriate standards for patent eligibility, few clear answers surfaced.
Supreme Court To Hear Prometheus Diagnostics Patent Case
The Supreme Court will take another stab at mapping out a border between patentable and unpatentable diagnostic method claims.